David Lazar, MD
Rheumatology · Myrtle Beach, SCNPI 1225320666
Payments from drug & device makers
Across 1,217 payments — averaging $92.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$91K
- E.r. Squibb & Sons, L.L.C.$7K
- Johnson & Johnson$3K
- Amgen$3K
- AbbVie$3K
- Novartis$2K
- plus $5K from 34 others
Across 13 payments — averaging $127.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 4 | $90,540 |
| E.r. Squibb & Sons, L.L.C. | 81 | $6,899 |
| Johnson & Johnson(2 entities) | 221 | $3,141 |
| Amgen(2 entities) | 276 | $3,138 |
| AbbVie | 187 | $2,550 |
| Novartis | 119 | $1,760 |
| UCB, Inc. | 146 | $1,544 |
| AstraZeneca | 26 | $508 |
| Genentech USA, Inc. | 26 | $427 |
| Novo Nordisk | 18 | $337 |
| Pfizer | 30 | $331 |
| GSK | 17 | $319 |
| Abbott | 11 | $234 |
| Astellas Pharma US Inc | 8 | $134 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Lilly USA, LLC | 6 | $85 |
| Radius Health, Inc. | 5 | $74 |
| Antares Pharma, Inc. | 3 | $43 |
| Dexcom, Inc. | 3 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Boston Scientific | 2 | $36 |
| Bristol Myers Squibb | 2 | $36 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Insulet Corporation | 2 | $28 |
| Organon | 1 | $28 |
| Corcept Therapeutics | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Bayer | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$112,673 in reported general payments places this provider in the 85th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Myrtle Beach
- Douglas ConawayMyrtle Beach$507K
- Gerald LarochelleMyrtle Beach$24K
- Wendy LeeMyrtle Beach$24K
- Rabih NayfeMyrtle Beach$21K
- Jon TwiningMyrtle Beach$14K
- David ChetritMyrtle Beach$8K
- Clarence LegertonSummerville$7.7M
- Gary FinkSummerville$6.9M
- William EdwardsSummerville$5.9M
- Colin EdgertonSummerville$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.